Molecular diagnostics in haematopathology

Diagnostic Histopathology

Volumn 14, Issue 5, 2008, Pages 223-235

  Byers, Richard ^a,b   Tholouli, Eleni ^a,b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b Manchester ^*  (United Kingdom)

Author keywords

haematological malignancy; microarray; molecular diagnosis; translocations

Indexed keywords

IMMUNOGLOBULIN; T LYMPHOCYTE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD DISEASE; CHRONIC MYELOID LEUKEMIA; CLONAL VARIATION; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MYELOPROLIFERATIVE DISORDER; PREDICTION; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 44949165602     PISSN: 17562317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2008.03.003     Document Type: Article

References (100)

1. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). WHO Classification of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon
2. Ebert B.L., and Golub T.R. Genomic approaches to hematologic malignancies. Blood 104 (2004) 923-932
3. Jack A. Organisation of neoplastic haematopathology services: a UK perspective. Pathology 37 (2005) 479-492
4. National Institute for Health and Clinical Excellence. Improving outcomes in haematological cancers (2003), National Institute for Health and Clinical Excellence, London
5. Dojcinov S.D., Attanoos R.L., O'Brien C.J., and Caslin A.W. Central pathological review of lymphomas in Wales and the identification of diagnostic discrepancies which impact on treatment. In: Marcus R., Cunningham D., and Miles A. (Eds). The effective management of non-Hodgkin's lymphoma (2001), Aesculapius Medical Press, London 33-54
6. Prescott R.J., Wells S., Bisset D.L., Banerjee S.S., and Harris M. Audit of tumour histopathology reviewed by a regional oncology centre. J Clin Pathol 48 (1995) 245-249
7. Youngson J.H., Jones J.M., Chang J.G., Harris M., and Banerjee S.S. Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study. Br J Cancer 72 (1995) 757-765
8. Bird C.C., Lauder I., Kellett H.S., et al. Yorkshire Regional Lymphoma Histopathology panel: analysis of five years' experience. J Pathol 143 (1984) 249-258
9. Jack A.S., and Morgan G.L. The development of haematopathology laboratories: a possible model for other pathology services. J Pathol 184 (1998) 231-233
10. van Dongen J.J., Langerak A.W., Brüggemann M., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17 (2003) 2257-2317
11. van Krieken J.H., Langerak A.W., Macintyre E.A., et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 21 (2007) 201-206
12. Evans P.A., Potty C., Groenen P.J., et al. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 21 (2007) 207-214
13. Brüggemann M., White H., Gaulard P., et al. Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia 21 (2007) 215-221
14. Langerak A.W., Molina T.J., Lavender F.L., et al. Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 21 (2007) 222-229
15. Sandberg Y., Verhaaf B., van Gastel-Mol E.J., et al. Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes. Leukemia 21 (2007) 230-237
16. Weiss L.M., Warnke R.A., Sklar J., and Cleary M.L. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 317 (1987) 1185-1189
17. Buchonnet G., Jardin F., Jean N., et al. Distribution of BCL2 breakpoints in follicular lymphoma and correlation with clinical features: specific subtypes or same disease?. Leukemia 16 (2002) 1852-1856
18. Limpens J., de Jong D., van Krieken J.H., et al. Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene 6 (1991) 2271-2276
19. Limpens J., Stad R., Vos C., et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 85 (1995) 2528-2536
20. Ohshima K., Kikuchi M., Kobari S., Masuda Y., Eguchi F., and Kimura N. Amplified bcl-2/JH rearrangements in reactive lymphadenopathy. Virchows Arch B Cell Pathol Incl Mol Pathol 63 (1993) 197-198
21. Bertoni F., Zucca E., and Cotter F.E. Molecular basis of mantle cell lymphoma. Br J Haematol 124 (2004) 130-140
22. Streubel B., Simonitsch-Klupp I., Müllauer L., et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 18 (2004) 1722-1726
23. Streubel B., Vinatzer U., Lamprecht A., Raderer M., and Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 19 (2005) 652-658
24. Ye H., Gong L., Liu H., et al. MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. J Pathol 205 (2005) 293-301
25. Montillo M., Hamblin T., Hallek M., Montserrat E., and Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 90 (2005) 391-399
26. Döhner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1910-1916
27. Crespo M., Bosch F., Villamor N., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348 (2003) 1764-1775
28. Orchard J.A., Ibbotson R.E., Davis Z., et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363 (2004) 105-111
29. Iida S., Rao P.H., Nallasivam P., et al. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 8 (1996) 4110-4117
30. Skinnider B.F., Horsman D.E., Dupuis B., and Gascoyne R.D. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol 30 (1999) 803-808
31. Lo Coco F., Ye B.H., Lista F., et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 83 (1994) 1757-1759
32. Katzenberger T., Ott G., Klein T., Kalla J., Müller-Hermelink H.K., and Ott M.M. Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. Am J Pathol 165 (2004) 481-490
33. Lossos I.S., Jones C.D., Warnke R., et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 98 (2001) 945-951
34. Hecht J.L., and Aster J.C. Molecular biology of Burkitt's lymphoma. J Clin Oncol 18 (2000) 3707-3721
35. Duyster J., Bai R.Y., and Morris S.W. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20 (2001) 5623-5637
36. Advani A.S., and Pendergast A.M. Bcr-Abl variants: biological and clinical aspects. Leuk Res 26 (2002) 713-720
37. Raanani P., Ben-Bassat I., Gan S., et al. Assessment of the response to imatinib in chronic myeloid leukemia patients-comparison between the FISH, multiplex and RT-PCR methods. Eur J Haematol 73 (2004) 243-250
38. Deininger M., Buchdunger E., and Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
39. Marin D., Kaeda J., Szydlo R., et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 19 (2005) 507-512
40. James C., Ugo V., Le Couédic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
41. Golub T.R., Barker G.F., Lovett M., and Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77 (1994) 307-316
42. Baxter E.J., Kulharni S., Vizmanos J.L., et al. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br J Haematol 120 (2003) 251-256
43. Giagounidis A.A., Germing U., Wainscoat J.S., Boultwood J., and Aul C. The 5q-syndrome. Hematology 9 (2004) 271-277
44. Melnick A., and Licht J.D. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93 (1999) 3167-3215
45. Reiter A., Lengfelder E., and Grmwade D. Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia. Acta Haematol 112 (2004) 55-67
46. Licht J.D. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 20 (2001) 5660-5679
47. Dimartino J.F., and Cleary M.L. Mll rearrangements in haematological malignancies: lessons from clinical and biological studies. Br J Haematol 106 (1999) 614-626
48. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99 (2002) 4326-4335
49. Murphy K.M., Levis M., Hafez M.J., et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn 5 (2003) 96-102
50. Golub T.R., Barker G.F., Bohlander S.K., et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 92 (1995) 4917-4921
51. Shurtleff S.A., Buijs A., Behm F.G., et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 9 (1995) 1985-1989
52. Raynaud S., Mauvieux L., Cayuela J.M., et al. TEL/AML1 fusion gene is a rare event in adult acute lymphoblastic leukemia. Leukemia 10 (1996) 1529-1530
53. Heerema N.A., Sather H.N., Sensel M.G., et al. Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group. J Clin Oncol 16 (1998) 1270-1278
54. Crist W., Carroll A., Shuster J., et al. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. Blood 76 (1990) 489-494
55. Khalidi H.S., O'Donnell M.R., Slovak M.L., and Arber D.A. Adult precursor-B acute lymphoblastic leukemia with translocations involving chromosome band 19p13 is associated with poor prognosis. Cancer Genet Cytogenet 109 (1999) 58-65
56. Uckun F.M., Nachman J.B., Sather H.N., et al. Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy. Leuk Lymphoma 33 (1999) 101-106
57. Ferrando A.A., Neuberg D.S., Staunton J., et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1 (2002) 75-87
58. Cavé H., Suciu S., Preudhomme C., et al. EORTC-CLG. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood 103 (2004) 442-450
59. Wadlow R., and Ramaswamy S. DNA microarrays in clinical cancer research. Curr Mol Med 5 (2005) 111-120
60. Golub T.R., Slonim D.K., Tamayo P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286 (1999) 531-537
61. Calin G.A., Pekarsky Y., and Croce C.M. The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20 (2007) 425-437
62. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
63. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B- cell lymphoma. N Engl J Med 346 (2002) 1937-1947
64. Shipp M.A., Ross K.N., Tamayo P., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8 (2002) 68-74
65. Robertson M.J., Kahl B.S., Vose J.M., et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25 (2007) 1741-1746
66. Hans C.P., and Weisenburger D.D. Greiner, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 (2004) 275-282
67. De Paepe P., and de Wolf-Peeters C. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia 21 (2007) 37-43
68. Nyman H., Adde M., Karjalainen-Lindsberg M.L., et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109 (2007) 4930-4935
69. Polo J.M., Juszczynski P., Monti S., et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci U S A 104 (2007) 3207-3212
70. Bende R.J., Smit L.A., and van Noesel C.J. Molecular pathways in follicular lymphoma. Leukemia 21 (2007) 18-29
71. Husson H., Carideo E.G., Neuberg D., et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood 99 (2002) 282-289
72. Glas A.M., Kersten M.J., Delahaye L.J., et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 105 (2005) 301-307
73. Dave S.S., Wright G., Tan B., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351 (2004) 2159-2169
74. Farinha P., Masoudi H., Skinnider B.F., et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106 (2005) 2169-2174
75. Lee A.M., Clear A.J., Calaminici M., et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 24 (2006) 5052-5059
76. Carreras J., Lopez-Guillermo A., Fox B.C., et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108 (2006) 2957-2964
77. Yang Z.Z., Novak A.J., Stenson M.J., Witzig T.E., and Ansell S.M. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107 (2006) 3639-3646
78. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
79. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92 (1998) 2322-2333
80. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (2001) 1752-1759
81. Doehner K., Tobis K., Ulrich R., et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 20 (2002) 3254-3261
82. Kroon E., Krosl J., Thorsteinsdottir U., et al. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 17 (1998) 3714-3725
83. Afonja O., Smith J.E., Cheng D.M., et al. MEIS1 and HOXA7 genes in human acute myeloid leukaemia. Leuk Res 24 (2000) 849-855
84. Thorsteinsdottir U., Kroon E., Jerome L., et al. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol 21 (2001) 224-234
85. Thorsteinsdottir U., Mamo A., Kroon E., et al. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 99 (2002) 121-129
86. Guo Q.M. DNA microarray and cancer. Curr Opin Oncol 15 (2003) 36-43
87. Bullinger L., Dohner K., Bair E., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350 (2000) 1605-1616
88. Valk P.J., Verhaak R.G., Beijen M.A., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350 (2004) 1617-1628
89. Ross M.E., Mahfouz R., Onciu M., et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 104 (2004) 3679-3687
90. Robertson K.D., Uzvolgyi E., Liang G., et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 27 (1999) 2291-2298
91. Mizuno S., Chijiwa T., Okamura T., et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 97 (2001) 1172-1179
92. Esteve P.O., Chin H.G., and Pradhan S. Proc Natl Acad Sci U S A 102 (2005) 1000-1005
93. Al-Taher A., Bashein A., Nolan T., Hollingsworth M., and Brady G. Global cDNA amplification combined with real-time RT-PCR: accurate quantification of multiple human potassium channel genes at the single cell level. Yeast 17 (2000) 201-210
94. Brady G., Barbara M., and Iscove N.N. Representative in vitro cDNA amplification from individual haemopoietic cells and colonies. Methods Mol Cell Biol (1990) 17-22
95. Iscove N.N., Barbara M., Gu M., Gibson M., Modi C., and Winegarden N. Representation is faithfully preserved in global cDNA amplified exponentially from sub-picogram quantities of mRNA. Nat Biotechnol 20 (2002) 940-943
96. Byers R., Roebuck J., Sakhinia E., and Hoyland J. PolyA PCR amplification of cDNA from RNA extracted from formalin-fixed paraffin-embedded tissue. Diagn Mol Pathol 3 (2004) 144-150
97. Sakhinia E., Farahangpour M., Tholouli E., et al. Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow. Br J Haematol 130 (2005) 233-248
98. Sakhinia E., Glennie C., Hoyland J.A., et al. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood 109 (2007) 3922-3928
99. Byers R.J., Di Vizio D., O'Connell F., et al. Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution. J Mol Diagn 9 (2007) 20-29
100. Tholouli E., Hoyland J.A., Di Vizio D., et al. Imaging of multiple mRNA targets using quantum dot based in situ hybridization and spectral deconvolution in clinical biopsies. Biochem Biophys Res Commun 348 (2006) 628-636